VEGFR1/Flt-1 Antibody [Biotin]

VEGFR1/Flt-1 was detected in immersion fixed paraffin-embedded sections of human breast array using Human VEGFR1/Flt-1 Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF321) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

VEGFR1/Flt-1 Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human VEGFR1/Flt-1
  Ser27-His687
  Accession # NP_001153392
• Specificity: Detects human VEGFR1 in ELISAs and Western blots. In sandwich immunoassays, less than 0.2% cross-reactivity with recombinant mouse VEGFR1, recombinant human (rh) VEGFR2, and rhVEGFR3 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FLT1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 0.1 ug/mL
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR1/Flt-1 Antibody [Biotin]

• EC 2.7.10
• EC 2.7.10.1
• FLT
• FLT1
• Flt-1
• Fms-like tyrosine kinase 1
• fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor)
• FRT
• Tyrosine-protein kinase FRT
• Tyrosine-protein kinase receptor FLT
• vascular endothelial growth factor receptor 1
• Vascular permeability factor receptor
• VEGF R1
• VEGFR1
• VEGFR-1

Background

Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) is a receptor tyrosine kinase that is expressed primarily on endothelial cells and plays a role in vasculogenesis and angiogenesis. A soluble variant of VEGFR1 was also reported to bind VEGF and PlGF with high affinity and function as a potent VEGF antagonist.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR1/Flt-1 Antibody (BAF321)(6)

Publications using BAF321

• Shun-Yun Cheng, Yongwen Luo, Anneliese Malachi, Jihye Ko, Qin Su, Jun Xie et al. Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis Human Gene Therapy 7/1/2021 [PMID: 34182803]
• J Cao, R Yang, TE Smith, S Evans, GW McCollum, SC Pomerantz, T Petley, IR Harris, JS Penn Human Umbilical Tissue-Derived Cells Secrete Soluble VEGFR1 and Inhibit Choroidal Neovascularization Mol Ther Methods Clin Dev, 2019-05-22;14(0):37-46. 2019-05-22 [PMID: 31276010] (Western Blot, Human)
• J Sánchez Ra, Y Morera Día, M Bequet-Rom, F Hernández-, KH Selman-Hou, A de la Torr, ER Santiesteb, Y Martín Bau, CH Bermúdez B, J de la Torr, JV Gavilondo, M Ayala Avil Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants BMC Immunol., 2017-07-26;18(1):39. 2017-07-26 [PMID: 28747172] (ELISA Development (Detection), Human)
• Altered Biomarkers in Trophoblast Cells Obtained Noninvasively Prior to Clinical Manifestation of Perinatal Disease Sci Rep, 2016-09-23;6(0):32382. 2016-09-23 [PMID: 27660926] (IHC, Human)
• Eichler W, Yafai Y, Keller T, Wiedemann P, Reichenbach A PEDF derived from glial Muller cells: a possible regulator of retinal angiogenesis. Exp. Cell Res., 2004-09-10;299(1):68-78. 2004-09-10 [PMID: 15302574] (Flow Cytometry, Western Blot, Human)
• Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur. J. Clin. Invest., 2003-10-01;33(10):883-90. 2003-10-01 [PMID: 14511360] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: FLT1
• Uniprot:
  • NP_001153392()